The PBS has signalled a move to subsidise dual combination therapy for patients with pulmonary arterial hypertension (PAH). A recommendation to subsidise combination therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE-5) inhibitor for patients with WHO Functional Class III and IV PAH was accepted by the Pharmaceutical Benefits Advisory Committee (PBAC) at its November ...
PBS funding recommended for dual combination therapy in PAH
By Michael Woodhead
18 Jan 2019